These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30685202)

  • 21. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ubiquitination in Scleroderma Fibrosis and Its Treatment.
    Long Y; Chen W; Du Q; Zuo X; Zhu H
    Front Immunol; 2018; 9():2383. PubMed ID: 30386338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.
    Yoshizaki A
    J Dermatol; 2016 Jan; 43(1):39-45. PubMed ID: 26782005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?
    Colletti M; Galardi A; De Santis M; Guidelli GM; Di Giannatale A; Di Luigi L; Antinozzi C
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487964
    [No Abstract]   [Full Text] [Related]  

  • 26. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
    Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
    J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis.
    Rossato M; Affandi AJ; Thordardottir S; Wichers CGK; Cossu M; Broen JCA; Moret FM; Bossini-Castillo L; Chouri E; van Bon L; Wolters F; Marut W; van der Kroef M; Silva-Cardoso S; Bekker CPJ; Dolstra H; van Laar JM; Martin J; van Roon JAG; Reedquist KA; Beretta L; Radstake TRDJ
    Arthritis Rheumatol; 2017 Sep; 69(9):1891-1902. PubMed ID: 28556560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit.
    Kakkar V; Assassi S; Allanore Y; Kuwana M; Denton CP; Khanna D; Del Galdo F
    Curr Opin Rheumatol; 2022 Nov; 34(6):357-364. PubMed ID: 36125916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis.
    Vlachogiannis NI; Pappa M; Ntouros PA; Nezos A; Mavragani CP; Souliotis VL; Sfikakis PP
    Front Immunol; 2020; 11():582401. PubMed ID: 33123169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models of scleroderma: lessons from transgenic and knockout mice.
    Derrett-Smith EC; Denton CP; Sonnylal S
    Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways.
    Bossini-Castillo L; López-Isac E; Martín J
    J Autoimmun; 2015 Nov; 64():53-65. PubMed ID: 26212856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel insights on the role of the innate immune system in systemic sclerosis.
    York MR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):481-9. PubMed ID: 21790291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.
    Saigusa R; Asano Y; Taniguchi T; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sugawara K; Tsuruta D; Taniguchi T; Sato S
    Proc Natl Acad Sci U S A; 2015 Dec; 112(49):15136-41. PubMed ID: 26598674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of leukotrienes in the pathogenesis of systemic sclerosis.
    Chwieśko-Minarowska S; Kowal K; Bielecki M; Kowal-Bielecka O
    Folia Histochem Cytobiol; 2012 Jul; 50(2):180-5. PubMed ID: 22763975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?
    Assassi S; Mayes MD
    Curr Opin Rheumatol; 2013 Nov; 25(6):686-91. PubMed ID: 24061076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
    Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
    Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances on pathogenesis and therapies in systemic sclerosis.
    Yazawa N; Fujimoto M; Tamaki K
    Clin Rev Allergy Immunol; 2007 Oct; 33(1-2):107-12. PubMed ID: 18064573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms.
    Zhao W; Yue X; Liu K; Zheng J; Huang R; Zou J; Riemekasten G; Petersen F; Yu X
    Rheumatol Int; 2017 Aug; 37(8):1303-1310. PubMed ID: 28434122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.